Hepatocyte transplantation as a treatment for glycogen storage disease type 1a
M Muraca, G Gerunda, D Neri, MT Vilei, A Granato… - The Lancet, 2002 - thelancet.com
M Muraca, G Gerunda, D Neri, MT Vilei, A Granato, P Feltracco, M Meroni, G Giron…
The Lancet, 2002•thelancet.comTreatment of many inherited disorders of hepatic metabolism is still challenging. Hepatocyte
transplantation was done in a 47-year-old woman who had glycogen storage disease type
1a and severe fasting hypoglycaemia. 2 billion viable hepatocytes were infused via an
indwelling portal-vein catheter, followed by a triple immunosuppression regimen with
mycophenolate mofetil, tacrolimus, and steroids. 9 months after transplantation, on only
tacrolimus, she eats a normal diet and can fast for 7 h without experiencing hypoglycaemia …
transplantation was done in a 47-year-old woman who had glycogen storage disease type
1a and severe fasting hypoglycaemia. 2 billion viable hepatocytes were infused via an
indwelling portal-vein catheter, followed by a triple immunosuppression regimen with
mycophenolate mofetil, tacrolimus, and steroids. 9 months after transplantation, on only
tacrolimus, she eats a normal diet and can fast for 7 h without experiencing hypoglycaemia …
Summary
Treatment of many inherited disorders of hepatic metabolism is still challenging. Hepatocyte transplantation was done in a 47-year-old woman who had glycogen storage disease type 1a and severe fasting hypoglycaemia. 2 billion viable hepatocytes were infused via an indwelling portal-vein catheter, followed by a triple immunosuppression regimen with mycophenolate mofetil, tacrolimus, and steroids. 9 months after transplantation, on only tacrolimus, she eats a normal diet and can fast for 7 h without experiencing hypoglycaemia. Our results show that hepatocyte transplantation might be an alternative to liver transplantation in glycogen storage disease type 1a.
thelancet.com